Structural basis for phospholipase A2-like toxin inhibition by the synthetic compound Varespladib (LY315920)

Detalhes bibliográficos
Autor(a) principal: Salvador, Guilherme H. M. [UNESP]
Data de Publicação: 2019
Outros Autores: Gomes, Antoniel A. S. [UNESP], Bryan-Quirós, Wendy, Fernández, Julián, Lewin, Matthew R., Gutiérrez, José María, Lomonte, Bruno, Fontes, Marcos R. M. [UNESP]
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UNESP
Texto Completo: http://dx.doi.org/10.1038/s41598-019-53755-5
http://hdl.handle.net/11449/198181
Resumo: The World Health Organization recently listed snakebite envenoming as a Neglected Tropical Disease, proposing strategies to significantly reduce the global burden of this complex pathology by 2030. In this context, effective adjuvant treatments to complement conventional antivenom therapy based on inhibitory molecules for specific venom toxins have gained renewed interest. Varespladib (LY315920) is a synthetic molecule clinically tested to block inflammatory cascades of several diseases associated with elevated levels of secreted phospholipase A2 (sPLA2). Most recently, Varespladib was tested against several whole snake venoms and isolated PLA2 toxins, demonstrating potent inhibitory activity. Herein, we describe the first structural and functional study of the complex between Varespladib and a PLA2-like snake venom toxin (MjTX-II). In vitro and in vivo experiments showed this compound’s capacity to inhibit the cytotoxic and myotoxic effects of MjTX-II from the medically important South American snake, Bothrops moojeni. Crystallographic and bioinformatics analyses revealed interactions of Varespladib with two specific regions of the toxin, suggesting inhibition occurs by physical blockage of its allosteric activation, preventing the alignment of its functional sites and, consequently, impairing its ability to disrupt membranes. Furthermore, based on the analysis of several crystallographic structures, a distinction between toxin activators and inhibitors is proposed.
id UNSP_5d69b5d3ff31e3f945809373d13e082e
oai_identifier_str oai:repositorio.unesp.br:11449/198181
network_acronym_str UNSP
network_name_str Repositório Institucional da UNESP
repository_id_str 2946
spelling Structural basis for phospholipase A2-like toxin inhibition by the synthetic compound Varespladib (LY315920)The World Health Organization recently listed snakebite envenoming as a Neglected Tropical Disease, proposing strategies to significantly reduce the global burden of this complex pathology by 2030. In this context, effective adjuvant treatments to complement conventional antivenom therapy based on inhibitory molecules for specific venom toxins have gained renewed interest. Varespladib (LY315920) is a synthetic molecule clinically tested to block inflammatory cascades of several diseases associated with elevated levels of secreted phospholipase A2 (sPLA2). Most recently, Varespladib was tested against several whole snake venoms and isolated PLA2 toxins, demonstrating potent inhibitory activity. Herein, we describe the first structural and functional study of the complex between Varespladib and a PLA2-like snake venom toxin (MjTX-II). In vitro and in vivo experiments showed this compound’s capacity to inhibit the cytotoxic and myotoxic effects of MjTX-II from the medically important South American snake, Bothrops moojeni. Crystallographic and bioinformatics analyses revealed interactions of Varespladib with two specific regions of the toxin, suggesting inhibition occurs by physical blockage of its allosteric activation, preventing the alignment of its functional sites and, consequently, impairing its ability to disrupt membranes. Furthermore, based on the analysis of several crystallographic structures, a distinction between toxin activators and inhibitors is proposed.Departamento de Física e Biofísica Instituto de Biociências Universidade Estadual Paulista (UNESP)Instituto Clodomiro Picado Facultad de Microbiología Universidad de Costa RicaCenter for Exploration and Travel Health California Academy of SciencesDepartamento de Física e Biofísica Instituto de Biociências Universidade Estadual Paulista (UNESP)Universidade Estadual Paulista (Unesp)Universidad de Costa RicaCalifornia Academy of SciencesSalvador, Guilherme H. M. [UNESP]Gomes, Antoniel A. S. [UNESP]Bryan-Quirós, WendyFernández, JuliánLewin, Matthew R.Gutiérrez, José MaríaLomonte, BrunoFontes, Marcos R. M. [UNESP]2020-12-12T01:05:49Z2020-12-12T01:05:49Z2019-12-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttp://dx.doi.org/10.1038/s41598-019-53755-5Scientific Reports, v. 9, n. 1, 2019.2045-2322http://hdl.handle.net/11449/19818110.1038/s41598-019-53755-52-s2.0-85075347831Scopusreponame:Repositório Institucional da UNESPinstname:Universidade Estadual Paulista (UNESP)instacron:UNESPengScientific Reportsinfo:eu-repo/semantics/openAccess2021-10-23T09:48:54Zoai:repositorio.unesp.br:11449/198181Repositório InstitucionalPUBhttp://repositorio.unesp.br/oai/requestopendoar:29462024-08-05T21:30:02.680897Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)false
dc.title.none.fl_str_mv Structural basis for phospholipase A2-like toxin inhibition by the synthetic compound Varespladib (LY315920)
title Structural basis for phospholipase A2-like toxin inhibition by the synthetic compound Varespladib (LY315920)
spellingShingle Structural basis for phospholipase A2-like toxin inhibition by the synthetic compound Varespladib (LY315920)
Salvador, Guilherme H. M. [UNESP]
title_short Structural basis for phospholipase A2-like toxin inhibition by the synthetic compound Varespladib (LY315920)
title_full Structural basis for phospholipase A2-like toxin inhibition by the synthetic compound Varespladib (LY315920)
title_fullStr Structural basis for phospholipase A2-like toxin inhibition by the synthetic compound Varespladib (LY315920)
title_full_unstemmed Structural basis for phospholipase A2-like toxin inhibition by the synthetic compound Varespladib (LY315920)
title_sort Structural basis for phospholipase A2-like toxin inhibition by the synthetic compound Varespladib (LY315920)
author Salvador, Guilherme H. M. [UNESP]
author_facet Salvador, Guilherme H. M. [UNESP]
Gomes, Antoniel A. S. [UNESP]
Bryan-Quirós, Wendy
Fernández, Julián
Lewin, Matthew R.
Gutiérrez, José María
Lomonte, Bruno
Fontes, Marcos R. M. [UNESP]
author_role author
author2 Gomes, Antoniel A. S. [UNESP]
Bryan-Quirós, Wendy
Fernández, Julián
Lewin, Matthew R.
Gutiérrez, José María
Lomonte, Bruno
Fontes, Marcos R. M. [UNESP]
author2_role author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Universidade Estadual Paulista (Unesp)
Universidad de Costa Rica
California Academy of Sciences
dc.contributor.author.fl_str_mv Salvador, Guilherme H. M. [UNESP]
Gomes, Antoniel A. S. [UNESP]
Bryan-Quirós, Wendy
Fernández, Julián
Lewin, Matthew R.
Gutiérrez, José María
Lomonte, Bruno
Fontes, Marcos R. M. [UNESP]
description The World Health Organization recently listed snakebite envenoming as a Neglected Tropical Disease, proposing strategies to significantly reduce the global burden of this complex pathology by 2030. In this context, effective adjuvant treatments to complement conventional antivenom therapy based on inhibitory molecules for specific venom toxins have gained renewed interest. Varespladib (LY315920) is a synthetic molecule clinically tested to block inflammatory cascades of several diseases associated with elevated levels of secreted phospholipase A2 (sPLA2). Most recently, Varespladib was tested against several whole snake venoms and isolated PLA2 toxins, demonstrating potent inhibitory activity. Herein, we describe the first structural and functional study of the complex between Varespladib and a PLA2-like snake venom toxin (MjTX-II). In vitro and in vivo experiments showed this compound’s capacity to inhibit the cytotoxic and myotoxic effects of MjTX-II from the medically important South American snake, Bothrops moojeni. Crystallographic and bioinformatics analyses revealed interactions of Varespladib with two specific regions of the toxin, suggesting inhibition occurs by physical blockage of its allosteric activation, preventing the alignment of its functional sites and, consequently, impairing its ability to disrupt membranes. Furthermore, based on the analysis of several crystallographic structures, a distinction between toxin activators and inhibitors is proposed.
publishDate 2019
dc.date.none.fl_str_mv 2019-12-01
2020-12-12T01:05:49Z
2020-12-12T01:05:49Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://dx.doi.org/10.1038/s41598-019-53755-5
Scientific Reports, v. 9, n. 1, 2019.
2045-2322
http://hdl.handle.net/11449/198181
10.1038/s41598-019-53755-5
2-s2.0-85075347831
url http://dx.doi.org/10.1038/s41598-019-53755-5
http://hdl.handle.net/11449/198181
identifier_str_mv Scientific Reports, v. 9, n. 1, 2019.
2045-2322
10.1038/s41598-019-53755-5
2-s2.0-85075347831
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Scientific Reports
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.source.none.fl_str_mv Scopus
reponame:Repositório Institucional da UNESP
instname:Universidade Estadual Paulista (UNESP)
instacron:UNESP
instname_str Universidade Estadual Paulista (UNESP)
instacron_str UNESP
institution UNESP
reponame_str Repositório Institucional da UNESP
collection Repositório Institucional da UNESP
repository.name.fl_str_mv Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)
repository.mail.fl_str_mv
_version_ 1808129326626897920